Atlanta, United States
Antios Therapeutics is a clinical-stage biopharmaceutical company committed to the development of therapies targeting viral diseases. Founded in 2018 and headquartered in the United States, the company leverages a strong leadership team to advance its flagship oral drug candidate, ushering in a new era of potentially curative treatments for HBV infections.
Operating within the Biopharma, Biotechnology, and Health and Wellness industries, Antios Therapeutics sets itself apart with a focus on innovation and clinically driven solutions. As it progresses through its clinical stages, it has already gained substantial backing, evident in its recent $75.00M Series B investment secured on 03 November 2021. This round was led by a consortium of distinguished investors including Pontifax, Domain Associates, Altium Capital, and GordonMD Global Investments, among others.
With its strategic focus and robust investor support, Antios Therapeutics is well-positioned to make significant advancements in the fight against viral diseases.
